Evidence map›Paper›PMID 32528472›Full record

ArticleFrontiers in immunology2020

Impact of Combinations of Donor and Recipient Ages and Other Factors on Kidney Graft Outcomes.

Maria Gerbase-DeLima, Renato de Marco, Franscisco Monteiro, Hélio Tedesco-Silva, José O Medina-Pestana, Karina L Mine

Open access · goldAbstract readComparative Study
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Optimizing the Use of Deceased Donor Kidneys at Risk of Discard: A Clinical Practice Guideline.Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Higher Donor Age and Severe Microvascular Inflammation Are Risk Factors for Chronic Rejection After Treatment of Active Antibody-Mediated Rejection.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Maria Gerbase-DeLimaInstituto de Imunogenética, Associação Fundo de Incentivo à Pesquisa, São Paulo, Brazil.
Renato de MarcoInstituto de Imunogenética, Associação Fundo de Incentivo à Pesquisa, São Paulo, Brazil.
Franscisco MonteiroSecretaria do Estado da Saúde, São Paulo, Brazil.
Hélio Tedesco-SilvaHospital do Rim, Fundação Oswaldo Ramos, São Paulo, Brazil.
José O Medina-PestanaHospital do Rim, Fundação Oswaldo Ramos, São Paulo, Brazil.
Karina L MineInstituto de Imunogenética, Associação Fundo de Incentivo à Pesquisa, São Paulo, Brazil.
Associação Fundo de Incentivo à Pesquisa · BRHospital do Rim e Hipertensão · BRSecretaria da Saúde · BRUniversidade Federal de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the availability of kidneys for transplantation continues to be outpaced by its growing demand, there has been an increasing utilization of older deceased donors in the last decades. Considering that definition of factors that influence deceased donor kidney transplant outcomes is important for allocation policies, as well as for individualization of post-transplant care, the purpose of this study was determine the risks for death censored graft survival and for patient survival conferred by older age of the donor in the context of the age of the recipient and of risk factors for graft and/or patient survival. The investigation was conducted in a single-center cohort of 5,359 consecutive first kidney transplants with adult deceased donors performed on non-prioritized adult recipients from January 1, 2002, to December 31, 2017. Death censored graft survival and patient survival were lower in older donors, whereas graft survival was higher and patient survival was lower in old recipients. The analyses of combinations of donor and recipient ages showed that death censored graft survival was lower in younger recipients in transplants from 18 to 59-year old donors, with standard or extended criteria, but no difference in graft survival was observed between younger and older recipients when the donor was ≥ 60-year old. Patient survival was higher in younger recipients in transplants with younger or older donors. Two to six HLA-A,B,DR mismatches, when compared to 0-1 MM, conferred risk for death-censored graft survival only in transplants from younger donors to younger recipients. Pre-transplant diabetes conferred risk for patient survival only in 50-59-year old recipients, irrespectively, of the age of the donor. Time on dialysis ≥ 10 years was a risk factor for patient survival in transplants with all donor-recipient age combinations, except in recipients with ≥ 60 years that received a kidney from an 18-49-year old donor. In conclusion, the results obtained in this study underline the importance of analyzing the impact of the age of the donor taking into consideration different scenarios.

Indexed as

Donor SelectionGraft SurvivalKidney TransplantationTransplant RecipientsAdolescentAdultAge FactorsFemaleHumansMaleMiddle AgedPostoperative ComplicationsRetrospective StudiesRisk AssessmentRisk FactorsTime Factorsdeath censored graft survivaldonor agekidney transplantationpatient survivalrecipient age

Identifiers

PMID32528472
PMCPMC7256929
OpenAlexW3026480683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.